NovoCure Limited (NVCR) IPO Opens Lower
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- S&P Global shares rise on report of possible CapIQ spinoff
NovoCure (NVCR) Launches 12.5M Common Stock IPO
October 2, 2015 6:09 AM EDTNovoCure Limited (Nasdaq: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by NovoCure Limited and 5,000,000 shares to be sold by selling shareholders. The initial public offer is currently expected to be between $26 and $29 per share. The underwriters for the offering will... More
NovoCure (NVCR) Trims IPO Expectations
October 1, 2015 2:10 PM EDTNovoCure Ltd. (Nasdaq: NVCR) filed an amended registration with the U.S. SEC today. The company now plans to offer 7.5 million ordinary shares and sees an offering price of $23 - $24 per share, from prior expectations of offering 12.5 million shares with an expected pricing... More
